Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoimmune liver diseases.

M P Manns1, R M Nakamura

  • 1Department of Basic and Clinical Research, Research Institute of Scripps Clinic, La Jolla, California.

Clinics in Laboratory Medicine
|June 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virological and clinical characteristics of delta hepatitis in Central Europe.

Journal of viral hepatitis·2009
Same author

Hepatitis C virus-specific T cell responses against conserved regions in recovered patients.

Vaccine·2009
Same author

Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology.

Zeitschrift fur Gastroenterologie·2009
Same author

[Liver transplantation: indications and results].

Der Internist·2009
Same author

[Transplantation medicine 2009].

Der Internist·2009
Same author

Transient autoimmune hepatitis induced by a thymoma.

The American journal of gastroenterology·2009

Autoimmune liver diseases like chronic active hepatitis and primary biliary cirrhosis involve immune system attacks on liver cells. Diagnosis relies on identifying specific autoantibodies, guiding potential treatments like immunosuppression or transplantation.

Area of Science:

  • Hepatology
  • Immunology
  • Autoimmune Diseases

Background:

  • Autoimmune-type chronic active hepatitis (AI-CAH) and primary biliary cirrhosis (PBC) are major autoimmune liver diseases.
  • The exact causes are unknown, but a loss of self-tolerance leads to immune-mediated destruction of hepatocytes (AI-CAH) or bile duct epithelia (PBC).
  • AI-CAH is a heterogeneous condition with distinct subgroups identifiable by specific autoantibodies.

Purpose of the Study:

  • To characterize autoimmune liver diseases, focusing on clinical, histologic, and immunopathologic aspects.
  • To explore the immune phenomena crucial for diagnosing AI-CAH and PBC.
  • To discuss the therapeutic implications of understanding these immune mechanisms.

Main Methods:

  • Review of clinical, histologic, and immunopathologic features of autoimmune liver diseases.

Related Experiment Videos

  • Analysis of circulating autoantibodies, including antinuclear antibodies (ANA), liver membrane autoantibodies (LMA), liver kidney microsomal antibodies (LKM), antibodies to soluble liver antigen (SLA), and antimitochondrial antibodies (AMA).
  • Correlation of serologic markers with disease subgroups and treatment responses.

    • Main Results:

    • AI-CAH can be subtyped based on autoantibody profiles (ANA, LMA, LKM, SLA), which has clinical relevance for treatment selection.
    • Specific autoantibodies, particularly antimitochondrial antibodies (AMA), characterize PBC.
    • Immunosuppressive therapy shows benefit in certain AI-CAH subgroups, while orthotopic liver transplantation is effective for end-stage PBC.

    Conclusions:

    • Understanding the immune phenomena in autoimmune liver diseases is key to diagnosis.
    • Serologic markers play a vital role in differentiating AI-CAH from other liver conditions and guiding therapy.
    • While effective medical treatments for PBC remain elusive, liver transplantation offers a viable option for advanced cases.